The National Coalition on Black Civic Participation (NCBCP) will host a historic celebration honoring Melanie L. Campbell’s ...

The Boys and Girls Club of County was one of eight clubs nationwide awarded funding to expand its science, technology, engineering and mathematics (STEM) programming. Timika Thrasher, the CEO of the ...

The third-quarter 2025 reporting cycle for the Medical sector is about to pick up pace this week, as most firms are slated to ...

Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,831.49 today based on a price of $120.19 for GILD at the time of writing.

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis with antibody-drug conjugates, suggest two trials presented at ESMO 2025.

Wall Street analysts expect Gilead Sciences (GILD) to post quarterly earnings of $2.15 per share in its upcoming report, which indicates a year-over-year increase of 6.4%. Revenues are expected to be ...

The Inflammatory Diseases Market, valued at USD 22.5 billion in 2025, is projected to reach USD 34.9 billion by 2035, ...

The WLA Prize is an international science award established at the forum in 2021. It aims to recognize exceptional ...

Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.

We asked five academics with expertise in sexual health, nutrition, psychiatry, bioethics and drug policy. Here’s what they said.